T2D Remission Buffers; Another Sotagliflozin Trial; More Gender-Affirming Care Bans?

People with any evidence of type 2 diabetes remission with diet and lifestyle changes had a 40% lower rate of cardiovascular disease and a 33% lower rate of chronic kidney disease versus those without remission, according to additional findings from the Look AHEAD study. (Diabetologia)

Among kids with overweight or obesity, the risk for developing type 2 diabetes was 72-fold higher in those with baseline HbA1c levels of 6.3% to 6.4% compared with those with a baseline level under 5.5%. (JAMA Network Open)

JDRF, formerly known as the Juvenile Diabetes Research Foundation, awarded $9 million to fund a pivotal clinical trial testing the dual SGLT1 and SGLT2 inhibitor sotagliflozin (Inpefa) in the treatment of kidney complications in patients with type 1 diabetes. The drug was rejected by the FDA for type 1 diabetes back in 2019 but nabbed an approval last year for a heart failure indication.

A Utah interventional endocrinologist performed the first thyroid microwave ablation procedure in the U.S. earlier this month, Baird Medical Devices announced.

Drinking cow’s milk may be protective against type 2 diabetes among lactase non-persistent individuals, possibly driven by involvement of gut microbiota and blood metabolites. (Nature Metabolism)

Improving social isolation and loneliness in people with obesity from the highest to lowest level reduced their all-cause mortality risk from 36% to 9%. (JAMA Network Open)

Price check for type 2 diabetes drugs in 2024: the list price for semaglutide (Ozempic) is up 3.5%, to roughly $970 for a month’s supply, while the price for tirzepatide (Mounjaro) jumped 4.5%, to about $1,070. (Becker’s Hospital Review)

Roughly 56% of patients remained about the same weight or continued to lose weight a year after stopping semaglutide (Ozempic, Wegovy) or liraglutide (Saxenda), according to an Epic Research study.

Ohio may become the second state to restrict gender-affirming care in adults. Meanwhile, state lawmakers in South Carolina approved a bill banning health professionals from providing gender-affirming care to minors. (AP)

An oral formulation of insulin reduced blood sugar levels without causing hypoglycemia in a baboon study. (Nature Nanotechnology)

Stress in adolescence was linked with greater cardiometabolic risk in young adulthood. (Journal of the American Heart Association)

The European Medicines Agency will consider wider use of the weight-loss formulation of semaglutide to reduce the risk of strokes and heart attacks. (Reuters)

Please enable JavaScript to view the

comments powered by Disqus.